Raptor Pharmaceutical Corp. (NASDAQ:RPTP)’s share price was down 4.6% during trading on Thursday . The company traded as low as $5.80 and last traded at $5.86, with a volume of 217,658 shares. The stock had previously closed at $6.14.

A number of equities analysts have recently commented on RPTP shares. Wedbush reiterated a “neutral” rating and set a $4.00 price target on shares of Raptor Pharmaceutical Corp. in a report on Friday, May 6th. Cowen and Company reiterated a “buy” rating and set a $8.00 price target on shares of Raptor Pharmaceutical Corp. in a report on Sunday, April 17th. Oppenheimer Holdings Inc. reiterated a “market perform” rating on shares of Raptor Pharmaceutical Corp. in a report on Monday, April 11th. Leerink Swann restated an “outperform” rating and issued a $11.00 target price on shares of Raptor Pharmaceutical Corp. in a report on Tuesday, April 12th. Finally, Zacks Investment Research lowered shares of Raptor Pharmaceutical Corp. from a “hold” rating to a “sell” rating in a report on Tuesday, May 3rd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $11.00.

The company’s market cap is $502.45 million. The firm’s 50-day moving average is $5.63 and its 200 day moving average is $4.78.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last issued its quarterly earnings results on Thursday, May 5th. The company reported ($0.17) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.17). The company earned $27.47 million during the quarter, compared to the consensus estimate of $27.17 million. Raptor Pharmaceutical Corp.’s quarterly revenue was up 34.3% on a year-over-year basis. During the same period in the previous year, the company earned ($0.24) EPS. Equities research analysts forecast that Raptor Pharmaceutical Corp. will post ($0.99) EPS for the current fiscal year.

A hedge fund recently raised its stake in Raptor Pharmaceutical Corp. stock. Cornerstone Capital Management Holdings LLC. raised its stake in shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) by 319.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 251,803 shares of the company’s stock after buying an additional 191,703 shares during the period. Cornerstone Capital Management Holdings LLC. owned 0.30% of Raptor Pharmaceutical Corp. worth $1,310,000 at the end of the most recent quarter.

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.